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Abstract
Smoking is one of the leading preventable threats to human health and a major
risk factor for lung cancer, upper aero-digestive cancer, and chronic obstructive pul-
monary disease. Estimating and forecasting the smoking attributable fraction (SAF)
of mortality can yield insights into smoking epidemics and also provide a basis for
more accurate mortality and life expectancy projection. Peto et al. (1992) proposed a
method to estimate the SAF using the lung cancer mortality rate as an indicator of
exposure to smoking in the population of interest. Here we use the same method to
estimate the all-age SAF (ASAF) for both genders for over 60 countries. We document
a strong and cross-nationally consistent pattern of the evolution of the SAF over time.
We use this as the basis for a new Bayesian hierarchical model to project future male
and female ASAF from over 60 countries simultaneously. This gives forecasts as well
as predictive distributions that can be used to find uncertainty intervals for any quan-
tity of interest. We assess the model using out-of-sample predictive validation, and
find that it provides good forecasts and well calibrated forecast intervals, comparing
favorably with other methods.
1 Introduction
Smoking is known to have adverse impacts on health and is one of the leading preventable
causes of death (Peto et al., 1992; Bongaarts, 2014; Mons and Brenner, 2017). It is a
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major risk factor for lung cancer, chronic obstructive pulmonary disease (COPD), respiratory
diseases, and vascular diseases, and tobacco use causes approximately 6 million deaths per
year (Britton, 2017). For instance, tobacco use causes more than 480,000 deaths per year in
the United States, accounting for about 20% of the total deaths of US adults, even though
smoking prevalence in United States has declined from 42% in the 1960s to 14% in 2018
(Mons and Brenner, 2017).
The smoking attributable fraction (SAF) is the proportion by which mortality would be
reduced if the population were not exposed to smoking. It is defined as
SAF =
nS
nD
,
where nS is the number of smokers who died because of their smoking habit and nD is the
total number of people who died. It can be shown that this is equivalent to
SAF =
p(r − 1)
p(r − 1) + 1 , (1)
where p is the underlying prevalence of smoking in the population and r is the risk of dying
of smokers divided by the risk of dying of nonsmokers in the population (Rosen, 2013).
Estimating and forecasting the SAF of mortality is essential for assessing how the smoking
epidemic influences mortality measures from the past to the future. First of all, nonlinear
patterns of increase in life expectancy over time are partially due to the smoking epidemic.
Bongaarts (2006) used the SAF to calculate the non-smoking life expectancy, which turned
out to evolve in a more linear fashion than overall life expectancy (including smoking effects).
Janssen et al. (2013) used a similar technique to calculate the non-smoking attributable
mortality, and showed that its decline is more linear than that of overall mortality.
Second, smoking partly accounts for regional variations in mortality. In most developed
regions in the world including Western Europe, North America and some East Asian coun-
tries, the smoking epidemic among males started earlier than elsewhere, in the first half of the
20th century. The adverse effect of the smoking epidemic accumulated for several decades,
leading to SAF peaking in these countries around the 1980s. With the continuous decline
of male smoking prevalence in these countries due to anti-smoking movements and tobacco
control, years of life lost due to smoking began to decrease in recent decades. In contrast,
many developing countries are currently in the early stage of the smoking epidemic, with
high and increasing smoking prevalence among males, even though tobacco control policies
are in place.
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Smoking also accounts for some subnational differences in mortality. For example,
Fenelon and Preston (2012) found that smoking accounts for the southern mortality disad-
vantage relative to other regions of the United States. They showed that smoking explained
65% of the subnational variation in male mortality in 2004.
Third, changes in smoking mortality largely account for changes in the between-gender
differences in mortality. The gap in mortality between males and females has tended to first
widen and then narrow in most developed countries, and reduced between-gender differences
in smoking largely explain the current closing of the between-gender mortality gap (Pampel,
2006; Preston and Wang, 2006). Indeed, in these countries the female smoking epidemic
usually started one or two decades later than the male epidemic, and thereafter followed a
similar pattern. In mid- to low-income countries, female smoking-related mortality remains
low but still follows a similar rising-peaking-falling trend to the male one. The SAF for
males and females clearly follows the same general increasing-peaking-decreasing trend but
with different times of onset, times-to-peak and maximum values (see Figure 1).
Therefore, estimating and forecasting the SAF can help to improve mortality forecasts
by taking the nonlinearity of mortality decline together with between-country and between-
gender differentials into account (Bongaarts, 2006; Janssen et al., 2013; Stoeldraijer et al.,
2015). Here we propose a new Bayesian hierarchical model to project SAF that captures
the observed increasing-peaking-declining trend so that it could be used for making better
mortality forecasts.
Estimating the SAF is not easy for several reasons (Bongaarts, 2014; Tachfouti et al.,
2014). First, the smoking habits of individuals can differ in terms of smoking intensity,
smoking history, types of tobacco used, as well as first-hand or second-hand smoking, so
that estimating the prevalence of smoking (p in Eq. 1) based on smoking behavior data is
not straightforward. Secondly, to estimate the relative risk of smoking (r in Eq. 1) requires
accurate cohort data. Such data are challenging to collect because smoking is not a direct
killer but rather has a lifelong impact, with deaths occurring mostly at older ages. The
American Cancer Society’s Cancer Prevention Study II (CPS-II), which began in 1982, is
so far the largest study that collects such data (Tachfouti et al., 2014). Thirdly, the quality
of registration and survey data varies across countries and between genders, which makes
estimation and comparison of SAF across countries difficult.
Three categories of methods have been proposed to estimate SAF. The first is prevalence-
based analysis in cohort studies (SAMMEC) (Levin, 1953). This uses estimated smoking
prevalence from surveys and relative risk from CPS-II. The second method is prevalence-
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based analysis in case-control studies. This method is similar to the first one, except that the
relative risk is estimated from a case-control study. It has been used for India (Gajalakshmi
et al., 2003), Hong Kong (Lam et al., 2001), and China (Niu et al., 1998). The main drawback
of prevalence-based methods is the scarcity of reliable historical data on smoking prevalence,
especially for developing countries.
The third method, which overcomes this limitation, is an indirect method. It is called
the Peto-Lopez method and was first proposed by Peto et al. (1992). This method estimates
the proportion of the population exposed to smoking using lung cancer mortality data, since
most lung cancer deaths are due to smoking in developed countries. According to Centers
for Disease Control and Prevention (2019), cigarette smoking is associated with more than
80% of lung cancer deaths in the United States. Simonato et al. (2001) also concluded by
case-control studies in 6 developed European countries that smoking is associated with over
90% of lung cancer cases. We use this method to estimate the SAF and we describe the
procedure in Section 2.3.
Another indirect method, the PGW method of Preston et al. (2009), also uses lung
cancer mortality rate as an indicator of the cumulative hazard of smoking. Instead of using
relative risks from the CPS-II as the Peto-Lopez method does, the PGW method adopts a
regression-based procedure. We discuss these two methods in Section 5.1. More comparisons
among different estimation methods of SAF can be found in Pe´rez-R´ıos and Montes (2008),
Tachfouti et al. (2014), Kong et al. (2016), and Peters et al. (2016).
Figure 1 plots the estimated all-age SAF (ASAF) of males and females for the United
States from 1950 to 2015. It can be seen that the evolution of SAF over time follows a
remarkably strong pattern, first rising and then falling. Qualitatively very similar patterns
were found in most countries that we studied, although in countries with less good data,
higher levels of measurement error can be seen. It seems intuitive to expect that such a
regular pattern could be used to obtain good forecasts. Here we describe our method for
doing this. It turns out that, indeed, good forecasts can be obtained, thanks to the strong
and consistent pattern of SAF over time. Here we propose a new probabilistic projection
method for the SAF using a Bayesian hierarchical model. Our method will provide estimates
and projections of the SAF for both genders jointly for more than 60 countries.
The paper is organized as follows. The data, the detailed SAF calculation based on the
Peto-Lopez method, and the proposed Bayesian hierarchical model are described in Section
2. An out-of-sample validation experiment is reported in Section 3. We then discuss general
estimation and forecasting results for all the countries considered in this work, with detailed
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Figure 1: United States: All-age smoking attributable fractions of mortality for males and
females from 1950 to 2015, estimated using the Peto-Lopez method.
case studies for four countries chosen from North America, South America, Asia, and Europe
in Section 4. We conclude with a discussion in Section 5.
2 Method
2.1 Notation
We use the symbol y to denote the estimated (observed) all-age smoking attributable fraction
(ASAF), which is defined as the smoking attributable fraction for all age groups combined,
and we use the symbol h to denote the true (unobserved) ASAF. All of these quantities are
indexed by country c, gender s, and year t. The quantities of interest are the unobserved
true past and present ASAF together with their future projections. Here the estimation
time period is 1950–2015 and the projection time period is 2015–2050. Section 2.3 describes
the estimation procedure for ASAF using the Peto-Lopez method for all available countries.
A Bayesian hierarchical model will be used to model the estimated ASAF. In the Bayesian
hierarchical model, the country-specific parameter vector determining the time evolution
pattern of ASAF for country c and gender s is denoted by θc,s, and the global parameters
by ψ.
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2.2 Data
We use the annual death counts by country, age group, gender, and cause of death from the
WHO Mortality Database (World Health Organization, 2017) which covers data from 1950
to 2015 for more than 130 countries and regions around the world. This dataset comprises
death counts registered in national vital registration systems and is coded under the rules of
the International Classification of Diseases (ICD). There are 5 raw datasets available by the
most recent update on 11 April 2018. The first three datasets are labeled as ICD versions
7, 8, and 9 respectively, and the last two are labeled as ICD version 10.
Each version of ICD codes causes of death differently and a summary of the codes used for
estimating ASAF in Section 2.3 is given in Table 1. For each country, the death counts data
can differ by geographical coverage, number of years available and age group breakdown.
Some countries such as China only have data from selected regions, and these countries will
not be included here.
We use the quinquennial population by five-year age groups from the 2017 Revision of
the World Population Prospects (United Nations, 2017) for each country, gender and age
group. Since this dataset provides population estimates at five-year intervals, we use linear
interpolation to obtain annual population estimates for each five-year age group.
2.3 ASAF Estimation
We apply the original Peto-Lopez indirect method to estimate ASAF for male and female
separately. This method uses the lung cancer mortality rate as an indicator of the accu-
mulated hazard of smoking to estimate the proportion of population exposed to smoking.
As commented in Peto et al. (1992), it is very rare to observe lung cancer cases among
non-smokers in developed countries, even in areas with pollution sources such as radon and
asbestos. The original papers (Peto et al., 1992, 1994, 2006) applied the method to developed
countries only, especially in Western Europe and North America. With the shift of global
smoking pattern, and diffusion of smoking in middle- and low-income countries, this method
has been extended to less developed countries (Ezzati and Lopez, 2003, 2004; Pampel, 2006).
For estimating ASAF using the Peto-Lopez method, we need first to estimate age- and
cause-of-death-specific SAF. The age groups used for estimation are 0-34, 35-59, 60-64, 65-
69, 70-74, 75-79, and 80+. For each age group, annual death counts of the following nine
categories of causes of death are obtained from the five raw datasets of WHO Mortality
Database: lung cancer, upper aero-digestive cancer, other cancers, COPD, other respiratory
diseases, vascular diseases, liver cirrhosis, non-medical causes, and all other medical causes.
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Table 1: ICD codes for different cause of death categories across versions.
Causes ICD-7 (A-list) ICD-8 (A-list) ICD-9 (09A, 09B)
Lung Cancer A050 A051 B101
Upper Aero-digestive Cancer A044, A045, A040 A045, A046, A050 B08, B090, B100
Other Cancer rest of A044-A059 rest of A045-A060 rest of B08-B14
COPD A092, A093 A093 B323, B324, B325
Other Respiratory rest of A087-A097 rest of A089-A096 rest of B31-B32
Vascular Disease A079-A086 A080-A088 B25-B30
Liver Cirrhosis A105 A102 A347
Other non-med A138-A150 A138-A150 B47-B56
Other medical rest rest rest
All causes A000 A000 B00
Causes ICD-9 (09N) ICD-10 (101) ICD-10 (103, 104, 10M)
Lung Cancer B101 1034 C33-C34
Upper Aero-digestive Cancer B08, B090, B100 1027, 1028, 1033 C00-C15, C32
Other Cancer rest of CH02 rest of 1027-1046 rest of C00-C97
COPD B323, B324, B325 1076 J40-J47
Other Respiratory rest of CH08 rest of 1072 J00-J99
Vascular Disease CH07 1064 I00-I99
Liver Cirrhosis S347 1080 K74, K70
Other non-med CH17 1095 V00-Y89
Other medical rest rest rest
All causes B00 1000 AAA
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A detailed list of codes from ICD 7, 8, 9, and 10 for these nine categories is provided in
Table 1.
The ICD categorizes death count data according to availability using so-called sublists,
which can be one of A-list or several others; see Table 1. The sublists we use are those
satisfying the minimum requirements for ASAF calculation. More specifically, for ICD 7 and
8, only countries whose ICD sublist is A-list are used. For ICD 9, only those countries whose
ICD sublist is 09A-, 09B-, or 09N-list are used. For ICD 10, countries whose ICD sublist is
one of 101-, 103-, 104-, 10M-list are used. In addition, we only calculate age-specific SAF
for countries whose age group breakdown is finer than the following age group breakdown:
0-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75+. This corresponds to the
age group format number 00, 01, 02, 03, 04 in the raw datasets.
To estimate the proportion of a population exposed to smoking, i.e., p in Eq. 1, the
method compares the observed lung cancer mortality rate with the lung cancer mortality
rate of smokers estimated from CPS-II. The estimated proportion, indexed by country c, age
group a, gender s, and year t, is estimated by
pc,a,s,t =
dc,a,s,t − dSa,s
dSa,s − dNSa,s
,
where dc,a,s,t is the observed country-age-gender-year-specific lung cancer mortality rate, and
dSa,s and d
NS
a,s are age-gender-specific lung cancer mortality rates for smokers and nonsmokers
from the CPS-II respectively. Here the observed lung cancer mortality rate dc,a,s,t is the
observed lung cancer death count divided by the population estimated from the 2017 Revision
of the World Population Prospects for country c, age group a, gender s, and year t.
The Peto-Lopez method uses the CPS-II to estimate the relative risk of dying for each
cause of death for smokers and nonsmokers, i.e., r in Eq. 1. Specifically, the Cochran-Mantel-
Haenszel method is used to estimate the relative risk for age group 35-59 by combining five
sub-age groups (35-39, 40-44, 45-49, 50-54, 55-59). The relative risk is indexed by cause-of-
death k, age group a, and gender s. Here k takes integer values 1-9 corresponding to the
nine categories mentioned above.
The excess mortality rate attributable to smoking is denoted by erk,a,s for cause-of-death
k, age group a, and gender s. For lung cancer, the excess mortality rate attributable to
smoking is calculated as er1,a,s = r1,a,s − 1. For all other categories except liver cirrhosis
(k = 7) and non-medical causes (k = 8), the excess risk is discounted by 50%, i.e., erk,a,s =
0.5(rk,a,s − 1) for k = 2, 3, 4, 5, 6, 9, so as to control for confounding factors. The excess
risks for liver cirrhosis and non-medical causes are set to 0, i.e., er7,a,s = er8,a,s = 0. The
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country-cause-age-gender-year-specific SAF, denoted by yc,k,a,s,t, is then
yc,k,a,s,t =
pc,a,s,t × erk,a,s
pc,a,s,t × erk,a,s + 1 .
Any estimated negative values are set to zero.
Since the hazard due to smoking is accumulated across years and mostly causes deaths
at older ages, the fraction of deaths due to smoking for ages 0-34 is typically very small
and is set to 0. In addition, the SAF for ages 80+ is set to the same value as that for ages
75-79 since smoking data are unreliable for very old ages. Finally, the country-gender-year-
specific ASAF, denoted by yc,s,t, is a weighted average of the age-specific smoking attributable
fractions yc,k,a,s,t. Thus
yc,s,t =
∑
a
∑
k
yc,k,a,s,t × dc,k,a,s,t,
where dc,k,a,s,t is the country-cause-age-gender-year-specific mortality rate.
We chose the Peto-Lopez method to estimate the ASAF because it has been validated
and widely used (Preston et al., 2009; Bongaarts, 2014; Tachfouti et al., 2014; Kong et al.,
2016). Also, the data required for the estimation are cause- and age-specific death counts
and population, which are provided with high quality by the WHO Mortality Database and
the 2017 Revision of the World Population Prospects.
There are some variants of the Peto-Lopez method, which also assume that the lung
cancer mortality rate is a good indicator for measuring smoking exposure. Some of the
modifications include using different relative risk estimation instead of the CPS-II to extend
the method to developing countries (Ezzati and Lopez, 2003) or using a regression-based
approach (Preston et al., 2009). Section 5.1 contains more detailed discussion and comparison
of these methods.
2.4 Model
We develop a four-level Bayesian hierarchical framework to model male and female ASAF
jointly for multiple regions simultaneously.
Random walk with drift for the true ASAF The observed ASAF data show a strong
and consistent pattern of increasing, then leveling, and then declining again for both genders
(Stoeldraijer et al., 2015) (see Figure 1 for the example of United States). This pattern can
be captured by the following five-parameter double logistic curve:
g(t|θ) = k
1 + exp{−a1(t− 1950− a2)} −
k
1 + exp{−a3(t− 1950− a2 − a4)} , (2)
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where t is the year of observation and θ is the double-logistic parameter vector, θ =
(a1, a2, a3, a4, k).
Models based on the double logistic curve have been used quite widely for human popula-
tion measures such as life expectancy and total fertility rates (Marchetti et al., 1996; Raftery
et al., 2013; Alkema et al., 2011)). Due to its natural scientific interpretability, the double
logistic curve has also been used in other scientific fields such as hematology (Head and
McCarty, 1987; Head et al., 2004), phenology (Yang et al., 2012), and agricultural science
(Shabani et al., 2018). This function has also been used to describe social change, diffusion,
and substitution processes (Gru¨bler et al., 1999; Fokas, 2007; Kucharavy and De Guio, 2011).
Most developed countries have had male smoking prevalence that started before 1950,
and peaked around the 1950s or 1960s when the adverse impacts of smoking on health
became known and tobacco control measures started being put in place. This led to a
peak in smoking-related mortality a generation or so later, followed by a continuous decline
since then. Pampel (2005) argued that the smoking epidemic involves diffusion from males
to females, and from more developed countries to less developed ones. Hence, the strong
increasing-peaking-decreasing trend of ASAF observed in most countries is a consequence of
the smoking epidemic diffusion process, and the double logistic curve can naturally describe
its dynamics.
For the five-parameter double logistic function in Eq. 2, a2 controls the first (left) inflec-
tion point of the curve and a4 controls the distance between the first (left) and the second
(right) inflection points. The rates of change at these inflection points are controlled by a1
and a3 respectively. The parameter k is an upper bound for the maximum value of the curve.
See the upper panel of Figure 2 for an illustration.
To represent this and also take account of the observed pattern of variability, we model
changes in the true ASAF between adjacent time points using a random walk with drift
given by the difference between the double logistic curve at the two points. This takes the
form
hc,s,t = hc,s,t−1 + g(t|θc,s)− g(t− 1|θc,s) + εhc,s,t, (3)
where g(·|θc,s) (i.e., Eq. 2) quantifies the expected change of the true ASAF governed
by the country- and gender-specific parameters θc,s = (a
c,s
1 , a
c,s
2 , a
c,s
3 , a
c,s
4 , k
c,s), and εhc,s,t are
independent Gaussian noises. This random walk with drift model is designed to capture
the variability of the true ASAF and allows the uncertainty of the forecast to increase when
projecting further into the future.
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Figure 2: Upper: The five-parameter double logistic curve. a2 controls the left inflection
point, a4 controls the distance between left and right inflections points, a1, a3 determine the
rate of change at left and right inflection points, and k approximates the maximum value.
Lower: The difference of country-specific am2 and a
f
2 plotted against the difference between
the country-specific peaks for males and females. The peak and a2 are estimated from the
countries whose male and female ASAF have all passed the maximum by 2015, according to
the results of the non-linear least squares estimation. The solid line is the 45 degree line.
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Male-female joint model Since the female smoking epidemic usually starts one to two
decades after the male one, the start of the increase in the female ASAF is also later than that
of the male ASAF. For most countries, the observed female ASAF is still in the increasing
or leveling phase up to 2015. However, as the smoking epidemic diffuses from the male
to the female population, it is reasonable to assume that the female ASAF will follow the
same trend of increasing-leveling-declining as that of the male ASAF. This has already been
observed for several countries with early smoking epidemics, such as the United Kingdom,
Denmark, and Japan (Pampel, 2005; Peto et al., 2006; Janssen et al., 2013; Bongaarts, 2014;
Stoeldraijer et al., 2015). For these countries, the female ASAF follows the same trend as
that of the male ASAF, but differs mainly in terms of the rate of increase or decrease, the
number of years taken to reach the peak, and the peak ASAF value.
For males, we need only estimate the rate of decline of the ASAF. For females, especially
for those countries whose observed ASAF data have not levelled yet, one needs first to
determine the time and value of leveling. By modeling male and female data jointly, the
lower panel of Figure 2 shows that for countries whose male and female ASAF both passed
the leveling period, the difference between the years of maximum of male and female is
approximately the same as the difference in the a2 parameter estimated from Eq. 2. The
a2 parameter represents the time point where the speed of the increasing part of the double
logistic curve begins to slow down.
The difference between the times-to-peak of male and female ASAF also differs among
countries. For example, the time-to-peak of the female ASAF in the United States is about
15 years later than that of the male ASAF, while the time-to-peak of the ASAF happened
at about the same time for both genders in Hong Kong. To incorporate these observa-
tions, we model the difference between male and female country-specific ac2 using a Gaussian
distribution:
ac,f2 = a
c,m
2 +4ca2 , 4ca2 |4a2 , σ24a2 ∼ N (4a2 , σ
2
4a2 ), (4)
where ac,m2 and a
c,f
2 are the country- and gender-specific values of a2, and 4ca2 is the country-
specific difference between these two parameters with prior mean 4a2 and variance σ24a2 .
Moreover, since there are very few countries whose female ASAF have begun to decline
by 2015, while the male ASAF has been declining for many years in most countries, we set
the same global parameters for the gender-specific parameters ac,m4 and a
c,f
4 for each country,
namely,
ac,m4 , a
c,f
4 |a4, σ2a4
ind∼ N (a4, σ2a4). (5)
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Except for ac4, the other four country-specific parameters of the double logistic curve are
conditioned on their own gender-specific global parameters.
Measurement error model for observed ASAF The observed country-gender-year-
specific ASAF yc,s,t are modeled based on the true (unobserved) ASAF hc,s,t by incorporating
measurement error due to the variability of data quality across different countries:
yc,s,t|hc,s,t, σ2c ∼ind N (hc,t,s, σ2c ). (6)
We assume that the variance of the observed ASAF for each country is time- and gender-
invariant based on exploratory analyses that indicate that the data quality is consistent
across time and between genders within the same country.
Summary of model We combine the Bayesian hierarchical model and measurement error
model into a four-level Bayesian hierarchical model. We model the observed ASAF estimates
using the measurement error model in Level 1, conditional on the true (unobserved) ASAF
data which are modeled with a random walk with drift in Level 2, conditional on the country-
specific parameters. Country-specific parameters are modeled in Level 3, where parameters
for male and female ASAF are modelled jointly conditional on the global parameters, whose
prior distributions are specified in Level 4.
The overall model is specified as follows:
Level 1: yc,s,t|hc,s,t ∼ N (hc,s,t, σ2c );
Level 2: hc,s,t0,c = g(t0,c|θc,s) + εhc,s,t0,c ,
hc,s,t = hc,s,t−1 + g(t|θc,s)− g(t− 1|θc,s) + εhc,s,t for t > t0,c,
εhc,s,t
ind∼ N (0, σ2h);
Level 3: θc,s ∼ f(·|ψ),
σ2c ∼ Lognormal(ν, ρ2);
Level 4: ψ, ν, ρ2, σ2h ∼ pi(·).
Here, t0,c is the year of the first available ASAF data for country c, g denotes the five-
parameter double logistic curve in Eq. 2, f denotes the conditional distribution of the
country-specific parameters θc,s, and pi denotes the hyperpriors for the global parameters
ψ, ν, ρ2, σ2h. The country-specific parameters θc,s = (a
c,s
1 , a
c,s
2 , a
c,s
3 , a
c,s
4 , k
c,s) are gender-specific
and the interaction between male and female parameters are governed by Eq. 4 and 5. The
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global parameters ψ = (am1 , a
m
2 , a
m
3 , a4, k
m, af1 , a
f
3 , k
f ,4a2 , σ2am2 , σ2a4 , σ2km , σ2kf , σ24a2 ) are also
gender-specific except for 4a2 , σ24a2 , a4, σ2a4 . More information about the specification of the
full model is given in the Appendix A.
Estimation and prediction Statistical analysis of the model is carried out in two phases,
estimation and prediction. The goal of the estimation phase is to obtain the joint posterior
distribution of the true ASAF hc,s,t during the estimation period 1950–2015 and the country-
specific parameters for the underlying double-logistic curve. The aim of the prediction phase
is to forecast the future ASAF of both genders for the prediction period 2015–2050 based on
the observed ASAF for over 60 countries whose male ASAF data are classifed as clear-pattern
(see Section 2.5 for the definition of clear-pattern).
The functional form of the prior distribution pi(·) is assessed using results from non-
linear least squares estimation based on clear-pattern countries (see Section 2.5 for details).
Specifically, the priors for (am1 , a
m
2 , a
m
3 , a4, k
m, σ2am2 , σ
2
a4
, σ2km , σ
2
am2
, σ2a4 , σ
2
km) are based on non-
linear least squares results from the male ASAF of over 60 clear-pattern countries, the prior
for af1 is estimated based on non-linear least squares results from the female ASAF of 52 clear-
pattern countries, the priors for (af3 , k
f , σ2
af3
) are set to the same priors as their counterparts
for males, while the priors for (4a2 , σ24a2 ) are estimated based on 19 countries for which both
male and female ASAF have passed the leveling stage by 2015. The priors for ν, ρ2, σ2h are
estimated by pooling male and female ASAF from all clear-pattern countries. A complete
specification of the model is given in the Appendix A.
2.5 ASAF Categorization
We categorize estimated ASAF for 127 countries and regions into two categories according
to the data availability and quality: clear-pattern and non-clear-pattern. On one hand,
the Peto-Lopez method is not guaranteed to produce reliable ASAF estimates for some less
developed countries because of poor data quality. On the other hand, modeling only with
clear-pattern countries can improve estimation and projection accuracy without introducing
too much random noise.
The classification is based on non-linear least squares estimation of the following model
for each country and gender separately:
yt = g(t|θ) + εt,
where g(t|θ) is as in Eq. 2 and εt are independent standard Gaussian errors. Its fit to the
data in a given country provides an indication of data quality for that country.
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Our categorization is based on the number of observations, maximum of observed values,
and the R2 value of the non-linear least squares fit. Due to the differences between the
diffusion processes of smoking in the male and female populations (Pampel, 2006), we use
different criteria for male and female data. For male data, we require that (1) the number
of available annual observations up to 2015 be greater than 10; (2) at least one of the
observations be greater than 0.05; and (3) that the R2 value be greater than 0.5.
For female data, since the smoking epidemic in general started one to two decades later
than the male one, the onset and the value of the ASAF is later and smaller than that of
the male epidemic (Pampel, 2005; Preston and Wang, 2006). The criteria for female data
are that (1) the number of observations up to 2015 be greater than 10; (2) at least one of
the observations be greater than 0.01; and (3) that the R2 value be greater than 0.6.
By these rules, there are over 60 countries whose male data are classifed as clear-pattern
(2 in Africa, 16 in the Americas, 9 in Asia, 40 in Europe and 2 in Oceania), and 52 countries
whose female data are classified as clear-pattern (12 in the Americas, 7 in Asia, 31 in Europe
and 2 in Oceania).
2.6 Estimation
Estimation is based on the male and female ASAF data from over 60 countries whose male
ASAF is classified as clear-pattern for the period 1950–2015. The reason why we chose clear-
pattern ASAF data is that non-clear-pattern data either have too few observations, very low
values, or their shapes are not identifiable.
We used the Rstan package (Version 2.18.2) in R to obtain the joint posterior distributions
of the parameters of interest (Carpenter et al., 2017). Rstan uses a No-U-turn sampler, which
is an adaptive variant of Hamiltonian Monte Carlo (Neal, 2011; Hoffman and Gelman, 2014).
We ran 3 chains with different initial values, each of length 10,000 iterations with a burn-in of
2,000 without thining. This yielded a final, approximately independent sample of size 8,000
for each chain. We monitored convergence by inspecting trace plots and using standard
convergence diagnostics.
We also conducted a sensitivity analysis on the hyperparameters that specify the priors
pi(·) for the global parameters ψ, and concluded that the proposed model is not sensitive to
the choice of hyperparameters. More information about the convergence diagnostics and the
sensitivity analysis is given in the Appendices B and C.
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2.7 Projection
We produce projections of future ASAF for the period 2015–2050 for over 60 countries whose
male ASAF is classified as clear-pattern. The prediction of future ASAF for each country
is based on past and present ASAF. We sample from the joint posterior distribution of the
country-specific parameters θc,s and of the past, and present true ASAF hc,s,t. We then
use Eq. 3 and 6 to generate a sample of trajectories of future true and observed ASAF
respectively from their joint posterior predictive distribution. It is possible that the quantity
generated by Eq. 3 and Eq. 6 is negative, and we set such values to zero. This yields
a sample from the joint posterior predictive distribution of the future ASAF for over 60
countries, for both genders, taking account of uncertainty about the past observations as
well as the future evolution. We include the plots of ASAF projections for both genders and
all countries considered in this work in the Appendix D.
3 Results
We assess the predictive performance of our model using out-of-sample predictive validation.
3.1 Study Design
The data we used for out-of-sample validation cover the period 1950–2015. We assess the
quality of our model based on different choices of estimation and validation data from the
observed data. Since the trend of increasing-leveling-declining pattern plays an important
role for estimation and projection, assessing how the model works when only part of the trend
has been observed is crucial. We consider different choices for estimation and validation
periods, namely (1) 1950– 2000 for estimation and 2000–2015 for validation; (2) 1950–2005
for estimation and 2005–2015 and for validation; and (3) 1950–2010 for estimation, 2010–
2015 for validation. The countries used for validation in each time-split scenario are required
to be clear-pattern countries based on the male ASAF, to contain more than 10 observations
in the estimation period, and to have at least one observation in the prediction period.
This results in 63, 66 and 66 countries used for validation under choices (1), (2) and (3),
respectively.
Since we are making probabilistic projections, our evaluation is based on both accuracy
of point prediction and calibration of prediction intervals. Our goal is not only to produce
accurate point predictions, but also to account for variability of future predictions based on
historic data, especially for those countries whose data in the estimation period reveal only
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part of the pattern. If the proposed model works well, we would expect the point predictor
to have small gender-specific mean absolute error (MAE), which is defined as
MAEs =
1
N
∑
c∈C
∑
t∈Tc
|yˆc,s,t − yc,s,t|, (7)
where C is the set of countries considered in the validation, Tc is the set of country-year
combinations used for validation, yˆc,s,t is the posterior median of the predictive distribution
of ASAF at year t for country c and gender s, and N is the total number of data used for
validation.
We wish the prediction to be well calibrated and sharp, i.e., the coverage of the prediction
interval to be close to the nominal level with its half-width as short as possible. Thus, we
include the empirical coverage and the half-width of the prediction interval in the validation.
To assess the overall predictive performance, we also calculate the gender-specific continuous
ranked probability score (CRPS) (Gneiting and Raftery, 2007), which is defined as
CRPSs =
1
|C|
∑
c∈C
[
1
|Tc|
∑
t∈Tc
∫ ∞
−∞
{Fc,s,t(y)− 1(yc,s,t ≤ y)}2dy
]
, (8)
where Fc,s,t(y) is the predictive distribution of the future ASAF for country c, gender s,
and time t, and 1(·) is equal to 1 if the condition in the parenthesis is satisfied and 0
otherwise. CRPS is a summary statistic measuring the quality of the probabilistic forecast,
which evaluates model calibration and sharpness simultaneously. The smaller the CRPS,
the closer the predictive distribution to the true data-generating distribution.
3.2 Out-of-sample Validation Results
To our knowledge, no other method is available in the literature to produce probabilistic
forecasts for male and female ASAF for developed and developing countries jointly. Janssen
et al. (2013) and Stoeldraijer et al. (2015) developed methods for projection of age-specific
SAF and age-standardized SAF, and their methods are based on age-period-cohort analysis,
which cannot be trivially extended to ASAF. See Section 5.2 for more discussion of their
procedures and comparison to the present ones.
As benchmarks against which to compare our method, we consider four other forecast
procedures. The first one is the persistence forecast, which takes the last observed value
as the forecast for the prediction period. The second method is the Bayesian thin plate
regression spline method (Wood, 2003), implemented in the mgcv package (Version 1.8-27)
in R. The third method is the Bayesian structural time series model (Harvey, 1990; Durbin
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and Koopman, 2012), implemented in the bsts package (Version 0.8.0) in R. Here we choose
to use two state components — local linear trend and autocorrelation with lag 1 — to
build the structural time series model. Our fourth comparison method is a non-hierarchical
version of our proposed model, namely our proposed model without Level 4 (i.e., the global
parameters). This is included to see whether the hierarchical structure is necessary.
We summarize the validation results in Table 2 for males and females separately. This
shows the MAE, the coverage and half-width of the prediction intervals, and the continuous
ranked probability score (CRPS). For males, our method improved the prediction accuracy
for all three scenarios over the persistence forecast. For forecasting one and two five-year
periods ahead, our method improved the MAE by 30% and 21% respectively. Since most male
ASAF series had passed the peak by 2005 and had experienced declines for several years, the
double logistic curve captures this trend well. For predictions three five-year periods into the
future, during which the male ASAF series for some countries were just reaching the peak,
our method still improved the MAE by 6%. For females, we observed similar improvements.
Our method decreased the MAE by 22%, 17%, and 27% for predictions one, two, and, three
five-year periods ahead compared to those of the persistence forecast.
Also, compared with other probabilistic forecast methods, our method produced shorter
prediction intervals with empirical coverages close to the nominal level for one and two five-
year predictions, while it produced prediction intervals with reasonably close to nomial for
the three five-year predictions for the male ASAF. On the other hand, since most female
ASAF series have not yet reached the peak, capturing the variability of future female ASAF
is essential. The coverage of our method is close to the nominal level, indicating that our
method is well calibrated.
Overall, our proposed BHM yielded the smallest CRPS among all methods in most cases
for both the male and female epidemics. Among all five methods compared in the validation
exercise, the Bayesian spline method was worst in terms of forecast accuracy, and tended
to underestimate the variability of future values. The Bayesian structural time series model
produced prediction interval close to the nominal level with slightly larger average half-
width than our method. However, a significant drawback of the persistence forecast, the
Bayesian spline method, and the Bayesian structural time series model is that they tend to
produce unrealistic forecasts when all the observed data are before the peak, since they do
not incorporate the increasing-peaking-decreasing information in the model. The left panel
of Figure 3 indicates that the Bayesian thin plate spline method projected a monotonically
increasing ASAF for United States female based on data before 2000, where the entire
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Figure 3: Forecast of US female ASAF based on data before 2000 using Bayesian spline
method (left) and Bayesian structural time series method (right). Observed ASAF values
are represented by black dots. The solid lines and dashed lines represent the posterior median
and the 95% prediction interval, respectively.
prediction interval missed the observed data after 2000. The right panel of Figure 3 shows
that the Bayesian structural time series model did cover the data but with an unrealistically
wide prediction interval.
The Bayesian model without the global level parameters produced results similar to
those from our BHM for projecting short term male ASAF. When forecasting three five-
year periods ahead, or the female ASAF, in both of which cases the peak has often not
been reached, the Bayesian model without the global level parameters was worse in accuracy
and CRPS. This indicates that the hierarchical structure did indeed improve the overall
forecast when only part of the trend has been observed, by sharing information among all
the countries.
Table 3 gives validation results for subgroups of countries, categorized by membership of
the Organization for Economic Cooperation and Development (OECD). Most of the countries
in the OECD are regarded as developed countries with high GDP and human development
index (HDI). For male ASAF, our BHM improved most of the forecasts for OECD coun-
tries, especially the longer term projections. For OECD countries, the increasing-peaking-
decreasing pattern is clearer and stronger, which fits with our modeling well. In contrast,
our BHM performed less well among non-OECD countries.
Figure 4 shows validation results for the male ASAF of four countries or regions for
19
Table 2: Predictive validation results for all-age smoking attributable fraction (ASAF). The
first and second columns indicate the estimation and validation periods . The “Gender” and
“n” columns indicate the gender and the number of countries used for the validation. In
the “Model” column, “Bayes” represents the Bayesian hierarchcial model with measurement
error and random walk with drift, “Bayes(S)” represents the same model as “Bayes” without
the global parameters, “Persistence” represents the persistence forecast, “Spline” represents
the Bayesian thin plate regression spline method, and “BSTS” represents the Bayesian struc-
tural time series method. The “MAE” column contains the mean absolute prediction error
defined by Eq. 7. The “Coverage” columns show the proportion of validation observations
contained in the 80%, 90%, 95% prediction intervals with their average half-widths in paren-
theses. The “CRPS” column contains the continuous ranked probability score defined by
Eq. 8.
Training Test n Gender Model MAE
Coverage
CRPS
80% 90% 95%
1950–2010 2010–2015 66
Male
Persistence 0.010 - - - -
Bayes 0.007 0.78 (0.011) 0.86 (0.014) 0.90 (0.017) 0.00523
Bayes(S) 0.007 0.86 (0.014) 0.94 (0.018) 0.97 (0.022) 0.00505
Spline 0.008 0.58 (0.009) 0.65 (0.011) 0.72 (0.013) 0.00648
BSTS 0.008 0.85 (0.015) 0.94 (0.020) 0.94 (0.025) 0.00570
Female
Persistence 0.009 - - - -
Bayes 0.007 0.83 (0.012) 0.93 (0.015) 0.96 (0.018) 0.00507
Bayes(S) 0.008 0.88 (0.014) 0.94 (0.018) 0.97 (0.022) 0.00538
Spline 0.010 0.42 (0.007) 0.52 (0.009) 0.61 (0.011) 0.00763
BSTS 0.008 0.80 (0.013) 0.89 (0.016) 0.94 (0.020) 0.00562
1950–2005 2005–2015 66
Male
Persistence 0.014 - - - -
Bayes 0.011 0.72 (0.014) 0.83 (0.018) 0.89 (0.022) 0.00797
Bayes(S) 0.010 0.85 (0.020) 0.93 (0.027) 0.97 (0.033) 0.00795
Spline 0.014 0.54 (0.014) 0.65 (0.018) 0.72 (0.021) 0.01096
BSTS 0.013 0.83 (0.026) 0.90 (0.035) 0.95 (0.043) 0.00989
Female
Persistence 0.012 - - - -
Bayes 0.010 0.80 (0.015) 0.90 (0.020) 0.92 (0.025) 0.00721
Bayes(S) 0.011 0.88 (0.021) 0.93 (0.028) 0.95 (0.035) 0.00808
Spline 0.014 0.44 (0.011) 0.51 (0.014) 0.58 (0.016) 0.01133
BSTS 0.011 0.77 (0.017) 0.88 (0.023) 0.93 (0.029) 0.00802
1950–2000 2000–2015 63
Male
Persistence 0.017 - - - -
Bayes 0.016 0.65 (0.020) 0.76 (0.026) 0.84 (0.031) 0.01214
Bayes(S) 0.018 0.84 (0.031) 0.92 (0.042) 0.95 (0.052) 0.01278
Spline 0.018 0.59 (0.019) 0.69 (0.024) 0.76 (0.029) 0.01335
BSTS 0.016 0.85 (0.039) 0.93 (0.053) 0.98 (0.068) 0.01281
Female
Persistence 0.015 - - - -
Bayes 0.011 0.81 (0.021) 0.90 (0.029) 0.95 (0.037) 0.00817
Bayes(S) 0.012 0.88 (0.027) 0.96 (0.039) 0.98 (0.050) 0.00887
Spline 0.016 0.48 (0.014) 0.59 (0.018) 0.70 (0.022) 0.01151
BSTS 0.012 0.79 (0.022) 0.89 (0.030) 0.94 (0.039) 0.00831
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Table 3: Predictive validation results for all-age smoking attributable fraction (ASAF) for
categories of countries. The “OECD” column represents whether the countries in the sub-
group belong to the OECD. The number of countries in the subgroup used for the validation
is in parentheses. All the other columns are the same as those in Table 2.
Training Test Gender OECD Model MAE
Coverage
CRPS
80% 90% 95%
1950–2010 2010–2015
Male
Y(34)
Persistence 0.011 - - - -
Bayes 0.006 0.81 (0.011) 0.90 (0.014) 0.95 (0.016) 0.00448
Bayes(S) 0.006 0.88 (0.013) 0.94 (0.017) 0.99 (0.021) 0.00459
Spline 0.007 0.60 (0.008) 0.67 (0.010) 0.73 (0.012) 0.00565
BSTS 0.007 0.86 (0.014) 0.95 (0.018) 0.98 (0.022) 0.00529
N(32)
Persistence 0.008 - - - -
Bayes 0.009 0.75 (0.011) 0.81 (0.015) 0.84 (0.018) 0.00601
Bayes(S) 0.008 0.85 (0.015) 0.92 (0.019) 0.94 (0.023) 0.00554
Spline 0.010 0.56(0.010) 0.63 (0.012) 0.70 (0.015) 0.00736
BSTS 0.009 0.86 (0.017) 0.95 (0.023) 0.98 (0.028) 0.00629
Female
Y(34)
Persistence 0.009 - - - -
Bayes 0.007 0.82 (0.011) 0.92 (0.015) 0.94 (0.018) 0.00505
Bayes(S) 0.008 0.86 (0.013) 0.93 (0.017) 0.96 (0.021) 0.00560
Spline 0.010 0.42 (0.007) 0.51 (0.008) 0.58 (0.010) 0.00762
BSTS 0.009 0.78 (0.012) 0.85 (0.015) 0.91 (0.019) 0.00616
N(32)
Persistence 0.008 - - - -
Bayes 0.008 0.83 (0.012) 0.95 (0.015) 0.95 (0.018) 0.00507
Bayes(S) 0.007 0.89 (0.015) 0.95 (0.019) 0.98 (0.023) 0.00516
Spline 0.011 0.42(0.008) 0.54 (0.010) 0.63 (0.012) 0.00764
BSTS 0.007 0.82 (0.013) 0.89 (0.017) 0.94 (0.021) 0.00506
1950–2005 2005–2015
Male
Y(34)
Persistence 0.016 - - - -
Bayes 0.010 0.73 (0.014) 0.85 (0.018) 0.90 (0.021) 0.00676
Bayes(S) 0.010 0.84 (0.019) 0.93 (0.025) 0.97 (0.032) 0.00717
Spline 0.013 0.52 (0.012) 0.61 (0.015) 0.69 (0.018) 0.01008
BSTS 0.012 0.85 (0.028) 0.91 (0.039) 0.97 (0.049) 0.01000
N(32)
Persistence 0.011 - - - -
Bayes 0.012 0.70 (0.014) 0.81 (0.019) 0.88 (0.022) 0.00928
Bayes(S) 0.011 0.87 (0.021) 0.93 (0.029) 0.96 (0.035) 0.00879
Spline 0.015 0.57 (0.016) 0.68 (0.020) 0.76 (0.024) 0.01189
BSTS 0.013 0.83 (0.026) 0.90 (0.035) 0.95 (0.043) 0.00989
Female
Y(34)
Persistence 0.012 - - - -
Bayes 0.009 0.82 (0.015) 0.92 (0.020) 0.95 (0.025) 0.00669
Bayes(S) 0.010 0.88 (0.019) 0.95 (0.025) 0.96 (0.032) 0.00736
Spline 0.012 0.38 (0.008) 0.45 (0.011) 0.52 (0.013) 0.00945
BSTS 0.012 0.82 (0.019) 0.90 (0.026) 0.92 (0.033) 0.00851
N(32)
Persistence 0.013 - - - -
Bayes 0.011 0.78 (0.015) 0.88 (0.020) 0.90 (0.025) 0.00780
Bayes(S) 0.012 0.88 (0.023) 0.91 (0.031) 0.93 (0.039) 0.00885
Spline 0.017 0.51 (0.013) 0.58 (0.017) 0.66 (0.020) 0.01333
BSTS 0.011 0.77 (0.017) 0.88 (0.023) 0.93 (0.029) 0.00802
1950–2000 2000–2015
Male
Y(33)
Persistence 0.018 - - - -
Bayes 0.014 0.67 (0.020) 0.79 (0.026) 0.88 (0.032) 0.01063
Bayes(S) 0.017 0.83 (0.030) 0.90 (0.040) 0.95 (0.050) 0.01221
Spline 0.017 0.58 (0.015) 0.68 (0.020) 0.74 (0.023) 0.01338
BSTS 0.018 0.88 (0.035) 0.93 (0.047) 0.97 (0.060) 0.01308
N(30)
Persistence 0.017 - - - -
Bayes 0.019 0.63 (0.020) 0.72 (0.026) 0.80 (0.031) 0.01377
Bayes(S) 0.018 0.86 (0.032) 0.93 (0.042) 0.95 (0.053) 0.01341
Spline 0.018 0.60 (0.022) 0.71 (0.029) 0.79 (0.034) 0.01331
BSTS 0.016 0.85 (0.045) 0.94 (0.063) 0.98 (0.082) 0.01308
Female
Y(33)
Persistence 0.016 - - - -
Bayes 0.011 0.80 (0.021) 0.89 (0.029) 0.95 (0.037) 0.00817
Bayes(S) 0.013 0.84 (0.028) 0.94 (0.038) 0.97 (0.048) 0.00981
Spline 0.016 0.41 (0.012) 0.54 (0.015) 0.62 (0.018) 0.01230
BSTS 0.011 0.73 (0.016) 0.86 (0.022) 0.92 (0.027) 0.00777
N(30)
Persistence 0.013 - - - -
Bayes 0.010 0.82 (0.017) 0.92 (0.023) 0.95 (0.030) 0.00699
Bayes(S) 0.010 0.93 (0.028) 0.98 (0.040) 0.99 (0.052) 0.00784
Spline 0.016 0.56 (0.017) 0.66 (0.022) 0.79 (0.026) 0.01066
BSTS 0.010 0.86 (0.022) 0.94 (0.030) 0.95 (0.039) 0.00735
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Figure 4: Validation of male all-age smoking attributable fraction for the United States,
Netherlands, Hong Kong, and Chile. Past observed ASAF values are shown by black dots
for 1950–2000 and by black squares for 2000–2015. The posterior median for 2000–2015 is
shown by the solid line, and the 80% and 95% prediction intervals are shown by the dotted
and dashed lines respectively.
predictions three five-year periods ahead. We see that our method works quite well for
the United States and Hong Kong, and the prediction interval captures the variability of
the male ASAF of Chile. Figure 5 shows the results from Scenario (1) where most female
ASAF of countries among the examples have not reached the peak by the year 2000. We see
that the posterior median of the predictive distribution captures the general trend of future
female ASAF of the United States, the Netherlands, and Chile reasonably well. For countries
or regions like Hong Kong whose female ASAF already passed the peak, our method also
accurately estimates the rate of decline.
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Figure 5: Validation of female all-age smoking attributable fraction for the United States,
Netherlands, Hong Kong, and Chile. Past observed ASAF values are shown by black dots
for 1950–2000 and by black squares for 2000–2015. The posterior median for 2000–2015 is
shown by the solid line, and the 80% and 95% prediction intervals are shown by the dotted
and dashed lines respectively.
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4 Case Studies
Probabilistic forecasts of ASAF to 2050 are given in the Appendix D for over 60 countries.
Broadly, the patterns in the OECD countries are similar, with male ASAF having declined
from about 30% in the 1990s to around 15% in 2015, with further declines projected to 2050,
reaching around 5%. The patterns vary more for females in OECD, and for both males
and females in non-OECD countries because they are currently at different stages of the
epidemic.
We now give four cases studies which illustrate various aspects of the proposed method
for estimating and forecasting ASAF.
4.1 United States
The annual ASAF for both male and female for the time period 1950–2015 is shown in Figure
1. The very clear pattern is due to the high quality of the data, reflecting the fact that the
United States has one of the the best vital registration systems in the world.
The smoking epidemic in the male population in the United States started in the earlier
1900s, and there was a substantial decrease of smoking prevalence and lung cancer mortality
rate after the 1950s. Smoking prevalence among US male adults was approximately 60% in
1950s, and went down to about 20% in the 1990s, and the general decline is still continuing
(Burns et al., 1997; Islami et al., 2015). The observed ASAF levelled around the 1990s and
declined afterwards. We forecast that by 2050, the median observed ASAF for US males
will be around 4.3% (with 95% prediction interval [0.0%, 8.3%]). Because the measurement
error for the US is tiny, the projected true ASAF (long dashed line for posterior mean and
dotted line for 95% prediction interval in Figure 6) for US males is almost equal to that of
the observed ASAF.
The female smoking epidemic started two decades later than the male one and the maxi-
mum prevalence was around 30% in the 1960s, and then declined to about 20% in the 1990s
(Burns et al., 1997). The pattern of smoking prevalence among US females is similar to
that for males, but around 20 years behind (Burns et al., 1997; Islami et al., 2015). The
female ASAF started to rise around the 1960s and reached its peak of 23% around 2005.
We forecast that by 2050, the median observed ASAF for US females will be around 2.7%
(with 95% prediction interval [0.0%, 9.3%]). Similarly, the projected US female true ASAF
follows closely with that of the observed ASAF. Figure 6 shows the historical records of the
observed male and female ASAF during the time period 1950–2015, along with projections
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Figure 6: United States: The left and right panels show the projection of ASAF up to 2050
under the proposed model for male and female respectively. The solid and long dashed
lines show the posterior median of projected observed ASAF and true ASAF respectively.
The dashed and dotted lines represent 95% prediction intervals for observed ASAF and true
ASAF respectively.
up to 2050 with posterior median and prediction intervals.
4.2 The Netherlands
The Netherlands is a high-income western Europe country whose smoking epidemic started
relatively early. Smoking prevalence reached 90% in the 1950s and dropped to 30% in the
2010s. The male observed ASAF in Netherlands passed its maximum ASAF around the
1990s and we project that it will go down to around 5.7% (with 95% prediction interval
[1.4%, 9.7%]) in 2050.
For females, smoking prevalence is also relatively high, and reached its peak of about
40% in the 1970s and dropped to 24% in the 2010s (Stoeldraijer et al., 2015). The female
ASAF in Netherlands is among the few that is already experiencing the leveling stage. By
our projection, the median year-to-peak for the female ASAF will be around 2020, which is
about 30 years after the male peak, and will reach 16.6% (with 95% prediction interval
[12.4%, 18.5%]). By 2050, the median observed female ASAF will be 4.7% (with 95%
prediction interval [0.0%, 19.3%]). Similarly to the case of US, the projected true ASAF
follows that of the observed ASAF closely, due to the small measurement error. Figure 7
shows the historical records of the observed male and female ASAF during time period 1950–
2015, and projections are given up to 2050 with posterior median and prediction intervals
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Figure 7: Netherlands: The left and right panels show the projection of ASAF up to 2050
under the proposed model for male and female respectively. The solid and long dashed
lines show the posterior median of projected observed ASAF and true ASAF respectively.
The dashed and dotted lines represent 95% prediction intervals for observed ASAF and true
ASAF respectively.
for both observed and true ASAF.
4.3 Hong Kong
Hong Kong has an advanced smoking epidemic, but had a decrease in male smoking preva-
lence from about 40% in the 1980s to 22% in 2000. A decline has also been observed in
female smoking prevalence, from 5.6% to 3.3% (Au et al., 2004). Like Japan, Singapore,
and South Korea, both male and female ASAF have passed the leveling stage and have been
declining for two decades. Unlike in most western developed countries, the time trend of the
ASAF has been almost identical for males and females in Hong Kong, with similar times
of onset and times-to-peak. Au et al. (2004) showed that the time trends of lung cancer
incidence were similar for both genders.
By our projection, the observed ASAF will reach 9.7% for males (with 95% prediction
interval [4.9%, 14.3%]) and 4.1% for females (with 95% prediction interval [0.0%, 8.1%]) by
2050. Compared with US and the Netherlands, the projected true ASAF of Hong Kong will
have narrower prediction intervals than those of the observed ASAF due to larger measure-
ment error exhibited in the historical data. However, the difference becomes less and less
since the majority uncertainty of the future ASAF will be account mainly by the variance
from the random walk model of the true ASAF.
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Figure 8: Hong Kong: The left and right panels show the projection of ASAF up to 2050
under the proposed model for male and female respectively. The solid and long dashed
lines show the posterior median of projected observed ASAF and true ASAF respectively.
The dashed and dotted lines represent 95% prediction intervals for observed ASAF and true
ASAF respectively.
As discussed by Lam et al. (2001), Hong Kong may be a good indicator for the future
development of the smoking epidemic and its impact on mortality in mainland China and
other developing countries. Figure 8 shows the historical records of the observed male and
female ASAF during time period 1950–2015, along with projections up to 2050 with posterior
median and prediction intervals.
4.4 Chile
Chile is one of the South America countries that have clear-pattern ASAF data for both
males and females. It also has relatively high smoking prevalence. A decline in prevalence
among males and females has been observed in recent years but is modest compared to the
decline in the United States (Islami et al., 2015). Also, female smoking prevalence is far
behind that of males.
Our method projects that the male ASAF will decline gradually. By 2050, the projected
median observed ASAF for the male population will be 4.3% (with 95% prediction interval
[0.0%, 9.1%]). For females, we expect an increase for another 10 years with the median
observed ASAF reaching the maximum 7.6% (with 95% prediction interval [2.0%, 11.8%])
by 2030. By 2050, the median observed female ASAF be 5.36% (with 95% prediction interval
[0.0%, 15.2%]); see Figure 9. Similarly to Hong Kong, Chile also has larger measurement error
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Figure 9: Chile: The left and right panels show the projection of ASAF up to 2050 under
the proposed model for male and female respectively. The solid and long dashed lines show
the posterior median of projected observed ASAF and true ASAF respectively. The dashed
and dotted lines represent 95% prediction intervals for observed ASAF and true ASAF
respectively.
and the pattern is less clear, so that the projected true ASAF has wider prediction intervals
compared with previous cases and the difference between true and observed projections also
appears in the short term.
5 Discussion
5.1 Comparison between SAF Estimation Methods
In Section 1, we briefly described three categories of estimation methods for SAF. Prevalence-
based methods depend heavily on smoking prevalence history. Since the lag between smoking
prevalence and SAF is usually around two or three decades, in order to use smoking preva-
lence to estimate and predict SAF, especially for those countries whose onset of SAF is before
1950, one needs data at least back to the 1920s or 1930s. However, such smoking prevalence
history is not available for most countries, and reconstruction of such data is challenging.
Ng et al. (2014) provided estimates of smoking prevalence for many countries only from 1980
onwards.
Insufficient historical data is a major obstacle to using smoking prevalence for estimation
and projection of SAF, and with currently available historical data, the predictive power us-
ing smoking prevalence data is not very high. In addition, smoking prevalence only reveals
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one aspect of the smoking epidemic, which cannot capture other aspects such as smoking
intensity and duration and thus has been argued to be a poor indicator of the smoking expo-
sure of the population (Shibuya et al., 2005; Luo et al., 2018). Prevalence-based estimation
and projection have generally been applied only to specific countries on an individual basis,
and examples include Taiwan (Wen et al., 2005) and the United States (Ma et al., 2018).
There are two main indirect methods used widely in the literature, which both use the
lung cancer mortality rate as an indicator for the accumulated hazard of smoking. The first
one is the Peto-Lopez method which we have used here. This has been widely used in the
demographic literature, in part because its data requirements are relatively modest. It has
been validated in many studies (Preston et al., 2009; Kong et al., 2016).
One drawback of the Peto-Lopez method is that it uses the CPS-II to estimate the rela-
tive risk. Since the CPS-II was conducted in 1982 with volunteer participants only from the
United States and most of them were middle-class, the CPS-II might not be fully represen-
tative and may potentially underestimate lung cancer mortality in nonsmokers (Tachfouti
et al., 2014). Moreover, the Peto-Lopez method assumes that the relative risk is constant
over time and homogeneous across nations. Mehta and Preston (2012), Teng et al. (2017),
and Lariscy et al. (2018) have shown that the risks from smoking are changing over time.
Also, in China and India, the lung cancer mortality rate among nonsmokers is higher than
that of the developed countries such as that in the CPS-II (Liu et al., 1998; Gajalakshmi
et al., 2003). Another issue is that the original Peto-Lopez paper reduced the smoking excess
risk of each cause-of-death except lung cancer by 50% to control for other confounders. As
stated in their paper, this reduction is somewhat arbitrary. To avoid some of these issues,
here we have used only data from clear-pattern countries, which avoids some countries for
which the Peto-Lopez method may not give good estimates.
Some variants of the Peto-Lopez method have been proposed. For example, Ezzati and
Lopez (2003) reduced the correction factor for excess risk from 50% to 30% for all countries
and extended this method to less developed countries by estimating the non-smoker lung
cancer mortality rate based on household use of coal in poorly-vented stoves. They also
provided an analysis of uncertainty. Mackenbach et al. (2004) used a simplified version
which only used the all-cause relative risk in the CPS-II study and avoided calculations for
the nine disease categories separately. Janssen et al. (2013) used this version to calculate
age-specific SAF to partition mortality into smoking and non-smoking attributable parts,
and projected them separately.
Muszyn´ska et al. (2014) and Stoeldraijer et al. (2015) used the same method to cal-
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culate an age-standardized SAF, whose purposes are to compare the role of smoking in
different regions of Poland, and to estimate and compare smoking attributable fraction of
mortality among England & Wales, Denmark and the Netherlands, respectively. While age-
standardization is used mainly to compare SAF among different populations, ASAF provides
the all-cause SAF with all age-groups aggregated and is the main quantity reported in the
iterature, e.g., Peto et al. (1992, 1994, 2006); Preston et al. (2009).
Based on these concerns about the Peto-Lopez method, Preston et al. (2009) and Preston
et al. (2011) came up with the PGW method, which used a regression-based method to
connect lung cancer mortality rate with other causes of death mortality rate instead of
using the CPS-II. The PGW method avoids the relative risk problem faced by the Peto-
Lopez method and provides estimates of uncentainty. However, its authors stated that the
Peto-Lopez method might work better for countries where the cause-of-death structure is
very different from that observed in developed countries, such as tropical African countries.
They also pointed out that both methods would not work well for countries whose lung
cancer mortality rate is also influenced largely by some other factors such as air pollution.
As discussed by Preston et al. (2009), the PGW method produces similar estimates to the
Peto-Lopez method in general for both males and females.
5.2 Projection Methodology
To our knowledge, there are only two other methods available for projecting SAF based on
the Peto-Lopez method. Janssen et al. (2013) proposed the first method to forecast age-
specific SAF and to our knowledge it has so far been applied only to the Netherlands. For
projecting male age-specific SAF, a constant decline rate (−1.5%) based on the current trend
of all-age combined SAF is applied for each age group. For females, it first estimates the
time-to-peak and value of peak of female SAF. It uses age-period-cohort (APC) analysis to
find the cohort with the highest lung cancer mortality rate and then adds 68, which is the
average age of dying from lung cancer, to that cohort to estimate the year which the all-age
combined female SAF would reach the maximum. Then the difference between year-to-peak
of male and female SAF with all ages combined is estimated and applied to get the time-to-
peak and thus the age-specific female SAF. Finally, the rate of decline of female age-specific
SAF is set to the same as that of the male.
The other method proposed for projecting SAF is to first estimate and project lung
cancer mortality rate by considering the cohort effect, and use it to calculate the age-specific
SAF. Stoeldraijer et al. (2015) used an APC model to estimate and forecast the lung cancer
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mortality rate of three countries: England & Wales, Denmark, and the Netherlands. For
female data, they first estimated the time-to-peak for each age group by assuming that
the time-to-peak of age-specific lung cancer mortality rate for females is when it reaches
the corresponding rate for males. By assuming that the female lung cancer mortality will
follow the same increasing-leveling-declining time trend as that for males for each age group,
the authors argued that their method could provide long-term projections of lung cancer
mortality rate, while previous work which only used historic trends in APC analysis could
only provide short-term projections.
APC analysis is widely used, but it is also plagued by the unidentifiability issue resulting
from the perfect linear relationship between the three effects. To resolve this requires extra
constraints on the parameter space, many of which are not desirable (Luo, 2013; Smith and
Wakefield, 2016). Also, projection of the future lung cancer mortality rate also requires the
projection of age, period, and cohort effects, which introduces additional projection error,
even more so for young cohorts for which historical data are not available.
Another way to resolve the unidentifiability issue in APC analysis is by introducing
cohort explanatory variables (Smith and Wakefield, 2016). Cohort smoking history is one
such powerful tool for estimating and projecting mortality. Preston and Wang (2006) and
Wang and Preston (2009) used the average year of smoking before 40 of a cohort as a
covariate to explain the mortality differences between genders and forecasted mortality of
United States for both genders up to 2035. Shibuya et al. (2005) and Luo et al. (2018) used
APC anlaysis with selected smoking covariates such as cigarette tar exposure to estimate
and project the lung cancer mortality rate. Cohort smoking history is a powerful tool, but it
requires additional data (Burns et al., 1997) that are not available for many of the countries
we considered.
5.3 China and India
According to Reitsma et al. (2017), China and India are the two countries that have seen
the largest percentage increase in smoking prevalence. As a result, the ASAF for these
two countries is important for understanding and projecting the world trend of the effect of
smoking on mortality since the diffusion of the smoking epidemic from developed countries
to developing countries has already started.
Parascandola and Xiao (2019) found that smoking-related health issues in China have
increased over the past two decades, and the trend resembles the early pattern observed in
high income countries such as the US and Japan. Smoking prevalence among Chinese men
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has remained high (around 60%) since the 1980s, with a modest decrease to 52% by 2015.
Smokers born after 1970 tended to start smoking earlier and more intensely than those born
before 1970.
Chen et al. (2015) analyzed two nationwide prospective cohort studies on smoking con-
ducted in China during 1991-99 and 2006-14. They found that the excess risk among smokers
almost doubled over the 15-year period. They reported that the SAF of males aged 40-79
increased from 11% in the first study to 18% in the second study, and they predicted that it
would be over 20% in the mid-2010s.
In contrast, female smoking prevalence decreased from 7% in the 1980s to 3% in 2015
(Parascandola and Xiao, 2019). However, second-hand smoking remains high among Chinese
females. Zheng et al. (2018) estimated that 65% of Chinese female non-smokers were exposed
to second hand smoking in 2012. Nonetheless, the SAF for Chinese females aged 40-79 years
was around 3% in 2006-14.
There are also substantial geographic differences in smoking prevalence. In big cities like
Beijing and Shanghai, smoking control measures have developed more rapidly than in other
areas.
India has become the country with the second largest cigarette consumption in the world,
after China. Smoking, including manufactured cigarettes, bidis, and chewing tobacco is one
of the major causes of death for middle-aged Indians. Mishra et al. (2016) estimated that
smoking prevalence among male Indians aged 15-69 years declined modestly from 27% in
1998 to 24% in 2010, while smoking prevalence among young adults aged 15-29 years rose.
We have not included these two countries in our analysis for the following two reasons.
Firstly, we do not have enough data to estimate the ASAF for China and India. Even though
there are some records of lung cancer death count data in the WHO Mortality Database for
China (World Health Organization, 2017), these are only regional data and so could be
biased. India has a reasonably good vital registration system but it also has lung cancer
mortality data only for selected regions and locations.
Secondly, as pointed out by Preston et al. (2009), neither the Peto-Lopez original method
nor the PGW method will provide reliable estimates of SAF for countries like China since
smoking is not the only major factor that can cause lung cancer. The main assumptions of
the Peto-Lopez and PGW methods are that lung cancer mortality is primarily caused by
smoking and that the lung cancer mortailty rate is very low among nonsmokers. Therefore,
as proposed by Ezzati and Lopez (2003) and others, some extra covariates such as household
use of coal in poorly-vented stoves are used to adjust the estimates. Incorporating China and
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India in the joint model could be feasible in the future if better ASAF estimation methods
and related data become available.
5.4 Decision-making and covariates
A main purpose of our method is to help improve mortality forecasts. One could also ask
whether our approach could be used directly for policy-making. One possible use would be
to provide a baseline forecast of what would happen with a continuation of current trends
in general health, development and tobacco control measures. This could help to assess the
effectiveness of additional policies in accelerating the decline of smoking-related mortality.
This could be done retrospectively, by considering a time point in the past at which a new
tobacco control policy was introduced, and then comparing the probabilistic forecast based
on data up to that point with what actually happened.
To do this prospectively would require the addition of covariates to the model. This is
challenging, and would be a good topic for further research. A difficulty with forecasting
using covariates is that the covariates themselves need to be forecast, and the covariates can
be harder to forecast than the quantity being forecast. This is especially the case when, as
here, the quantity being forecast has a strong time trend, and thus may well itself be easier
to forecast than the covariates. In this situation, adding covariates can lead to forecasts that
are noisier. This is one reason why, after decades of research, the majority of demographic
studies do not use covariates in forecasting demographic quantities.
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Appendices
A Full Bayesian Hierarchical Model
The details of the four-layer Bayesian Hierarchical model described in Section 2.4 are as
follows. HereN ul (a, b) represents a normal distribution with mean a and variance b truncated
at interval [l, u] (l(u) is omitted if it takes value −∞ (∞)). Gamma(a, b) represents a Gamma
distribution with shape a and rate b. Lognormal(a, b) represents a log-normal distribution
with parameters a, b. InvGamma(a, b) represents a inverse-Gamma distribution with shape
a and scale b.
Level 1: yc,s,t|hc,s,t ∼ N (hc,s,t, σ2c );
Level 2: hc,s,t0 = g(t0|θc,s) + εhc,s,t0 ,
hc,s,t = hc,s,t−1 + g(t|θc,s)− g(t− 1|θc,s) + εhc,s,t for t > t0,
εhc,s,t ∼ind N (0, σ2h);
Level 3: ac,m1 ∼ Gamma(2, 2/am1 ), ac,f1 ∼ Gamma(2, 2/af1),
ac,m2 ∼ N 65(am2 , σ2am2 ), a
c,f
2 = a
c,m
2 +4ca2 ,
ac,m3 ∼ Gamma(2, 2/am3 ), 4ca2 ∼ N (4a2 , σ24a2 ),
ac,m4 ∼ N 1000 (a4, σ2a4), ac,f3 ∼ Gamma(2, 2/af3),
kc,m ∼ N0(km, σ2km), ac,f4 ∼ N 1000 (a4, σ2a4),
σ2c ∼ Lognormal(ν, ρ2), kc,f ∼ N0(kf , σ2kf );
Level 4: am1 ∼ Gamma(αam1 , βam1 ), af1 ∼ Gamma(αaf1 , βaf1 ),
am2 ∼ N (αam2 , βam1 ), 4a2 ∼ N (α4a2 , β4a2 ),
am3 ∼ N (αam3 , βam3 ), af3 ∼ Gamma(αaf3 , βaf3 ),
a4 ∼ N (αa4 , βa4), kf ∼ N (αkf , βkf ),
km ∼ N (αkm , βkm), σ24a2 ∼ InvGamma(ασ24a2 , βσ24a2 ),
σ2am2 ∼ InvGamma(ασ2am2 , βσ2am2 ), σ
2
kf ∼ InvGamma(ασ2
kf
, βσ2
kf
),
σ2a4 ∼ InvGamma(ασ2a4 , βσ2a4 ), ν ∼ N (αν , βν),
σ2km ∼ InvGamma(ασ2km , βσ2km ), ρ
2 ∼ InvGamma(αρ2 , βρ2),
σ2h ∼ InvGamma(ασ2h , βσ2h),
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where αam1 = 1.477, βam1 = 9.423, αam2 = 24.362, βam2 = 12.488, αam3 = 1.031, βam3 = 7.378, αa4 =
38.362, βa4 = 19.058, αkm = 0.362, βkm = 0.255, ασ2am2
= 2, βσ2
am2
= 12.4882, ασ2a4 = 2, βσ
2
a4
=
19.0582, ασ2km = 2, βσ2km = 0.255
2, αaf1
= 2.093, βaf1
= 16.302, α4a2 = 12.080, β4a2 = 11.140, αaf3 =
1.031, βaf3
= 7.378, αkf = 0.362, βkf = 0.255, ασ24a2
= 2, βσ24a2
= 112, ασ2
kf
= 2, βσ2
kf
=
0.2552, αν = −10.414, βν = 1.1862, αρ2 = 2, βρ2 = 1.1862, ασ2h = 2, βσ2h = 0.012.
B MCMC Convergence Diagnostics
B.1 Hyperparameter Diagnostics
In this section, we present the MCMC convergence diagnostics of the hyperparameters in
Level 4 of the model in terms of traceplots, Raftery diagnostic statistics (Raftery and Lewis,
1992), and Gelman diagnostic statistics (Gelman and Rubin, 1992). Table 4 provides the
Gelman and Raftery diagnostic statistics of all hyperparameters. We use 3 chains with 2000
burnin and 8000 samples without thinning for the Gelman diagnostics, and randomly choose
one of the chain to perform the Raftery diagnostics. Figure 10 shows the traceplots of all
8000 samples of hyperparameters.
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Table 4: Diagnostic statistics for hyperparameters. PSRF and 95% UCI are the point
estimator and upper bound of the 95% CI of the Gelman potential scale reduction factor.
Burn1, Size1, and DF1 are the length of burn-in, requied sample size, and dependent factor of
Raftery diagnostics with parameters q = 0.025, r = 0.0125, s = 0.95. Burn2, Size2, and DF2
are the length of burn-in, requied sample size, and dependent factor of Raftery diagnostics
with parameters q = 0.975, r = 0.0125, s = 0.95.
Parameters
Gelman Diag Raftery Diag
PSRF 95% UCI Burn1 Size1 DF1 Burn2 Size2 DF2
am1 1 1.00 6 1318 2.20 6 1164 1.94
am2 1 1.00 3 710 1.18 6 1504 2.51
am3 1 1.00 6 1584 2.64 6 1424 2.37
a4 1 1.01 8 1750 2.92 9 2028 3.38
km 1 1.01 10 1952 3.25 6 1236 2.06
σ2am2 1 1.00 2 640 1.07 6 1730 2.88
σ2a4 1 1.00 21 4410 7.35 12 2132 3.55
σ2km 1 1.00 6 1334 2.22 8 1448 2.41
af1 1 1.00 2 640 1.07 6 1318 2.20
4a2 1 1.00 4 756 1.26 6 688 1.15
af3 1 1.00 8 1504 2.51 12 1852 3.09
kf 1 1.00 5 895 1.49 2 640 1.07
σ24a2 1 1.00 3 696 1.16 4 839 1.40
σ2
kf
1 1.00 2 640 1.07 6 1376 2.29
ν 1 1.00 8 1518 2.53 8 1934 3.22
ρ2 1 1.00 6 1270 2.21 6 1392 2.32
σ2h 1 1.00 10 1872 3.12 12 2337 3.90
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Figure 10: Traceplots for the hyperparameters.
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B.2 Country-specific Parameter Diagnostics
In this section, we present the MCMC convergence diagnostics of country-specific parameters
of the model in terms of traceplots, Raftery diagnostic statistics, and Gelman diagnostic
statistics. Table 5 provides the Gelman and Raftery diagnostic statistics of country-specific
parameters of the United States for male and female. The chains are the same as in the
previous section. Figure 11 shows the traceplots of all 8000 samples of country-specific
paremeters for male and female of the United States.
Table 5: Diagnostic statistics for country-specific parameters for the United States. PSRF
and 95% UCI are the point estimator and upper bound of the 95% CI of the Gelman potential
scale reduction factor. Burn1, Size1, and DF1 are the length of burn-in, requied sample size,
and dependent factor of Raftery diagnostics with parameters q = 0.025, r = 0.0125, s = 0.95.
Burn2, Size2, and DF2 are the length of burn-in, requied sample size, and dependent factor
of Raftery diagnostics with parameters q = 0.975, r = 0.0125, s = 0.95.
Parameters
Gelman Diag Raftery Diag
PSRF 95% UCI Burn1 Size1 DF1 Burn2 Size2 DF2
am1 1 1.00 4 830 1.38 2 640 1.07
am2 1 1.00 6 1326 2.21 4 756 1.26
am3 1 1.00 4 822 1.37 2 633 1.06
am4 1 1.00 2 614 1.02 4 772 1.29
km 1 1.00 6 1106 1.10 2 621 1.03
af1 1 1.00 3 661 1.10 2 614 1.02
af2 1 1.00 2 627 1.04 2 614 1.02
af3 1 1.00 2 627 1.04 6 1314 2.19
af4 1 1.00 3 661 1.10 4 848 1.41
kf 1 1.00 3 668 1.11 6 1444 2.41
σ2c 1.01 1.03 96 15198 25.30 24 3834 6.39
45
Figure 11: Traceplots for the country-specific parameters of the United States.
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C Hyperparameter Sensitivity Analysis
In this section, we present the sensitivity analysis for the hyperparameters set in pi(·) on
the posterior distributions of the global parameters ψ in Level 4 of our model. We use
rstansensitivity package (Giordano, 2019) in R to perform the sensitivity analysis. The
local sensitivity of the posterior mean of parameter θ under hyperparameters ζ (i.e., E(θ|x, ζ))
to ζ at ζ0 is defined as
Sζ0 :=
dE(θ|x, ζ)
dζ
∣∣∣
ζ0
,
where x is the observed data (cf. Basu et al. (1996), Gustafson (1996), and Giordano et al.
(2018) for more discussions on local sensitivity in Bayesian analysis). By scaling the local
sensitivity to be comparable with the possible range of the posterior distribution of θ, the
normalized local sensitivity is defined as
S˜ζ0 :=
∣∣∣∣ Sζ0sd(θ|x, ζ0)
∣∣∣∣.
As commented in Giordano et al. (2018), if the quantity S˜ζ0 is less than 1 or if S˜ζ0 is greater
than 1 but the final results barely change when modifying the hyperparameters, then the
model is robust. First of all, Table 6 investigates the normalized local sensitivity of the
hyperparameters set in pi(·) on posterior distributions of the global parameters ψ. For most
hyperparameters, the normalized local sensitivity are much smaller than 1. For those whose
normalized local sensitivity are greater than 1, we conduct out-of-sample validations for three
five-year period prediction with the hyperparameters changed to evaluate the actual changes
on the validation results. Table 7, 8, 9, and 10 show the out-of-sample validtion results after
modifying βσ2km
(0.2552 to 1), βσ2kf
(0.2552 to 1), βσ2h (0.01
2 to 0.022), and αa4 (38.362 to 20),
respectively. All four cases show that the validation results barely change, and we conclude
that model is robust under the current choices of hyperparameters.
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Table 7: Out-of-sample validation results of ASAF for both male and female with βσ2km
changed. “Bayes (mod)” is the BHM with changed hyperparameter.
Gender Train Test num Method MAE
Coverage
80% 90% 95%
Male 1950-2000 2000-2015 63
Bayes(mod) 0.016 0.63 0.76 0.85
Bayes 0.016 0.65 0.76 0.84
Female 1950-2000 2000-2015 63
Bayes(mod) 0.011 0.80 0.89 0.94
Bayes 0.011 0.81 0.90 0.95
Table 8: Out-of-sample validation results of ASAF for both male and female with βσ2kf
changed. “Bayes (mod)” is the BHM with changed hyperparameter.
Gender Train Test num Method MAE
Coverage
80% 90% 95%
Male 1950-2000 2000-2015 63
Bayes(mod) 0.016 0.64 0.77 0.85
Bayes 0.016 0.65 0.76 0.84
Female 1950-2000 2000-2015 63
Bayes(mod) 0.011 0.82 0.90 0.95
Bayes 0.011 0.81 0.90 0.95
Table 9: Out-of-sample validation results of ASAF for both male and female with βσ2h
changed. “Bayes (mod)” is the BHM with changed hyperparameter.
Gender Train Test num Method MAE
Coverage
80% 90% 95%
Male 1950-2000 2000-2015 63
Bayes(mod) 0.016 0.68 0.80 0.88
Bayes 0.016 0.65 0.76 0.84
Female 1950-2000 2000-2015 63
Bayes(mod) 0.011 0.82 0.90 0.95
Bayes 0.011 0.81 0.90 0.95
Table 10: Out-of-sample validation results of ASAF for both male and female with αa4
changed. “Bayes (mod)” is the BHM with changed hyperparameter.
Gender Train Test num Method MAE
Coverage
80% 90% 95%
Male 1950-2000 2000-2015 63
Bayes(mod) 0.016 0.65 0.76 0.85
Bayes 0.016 0.65 0.76 0.84
Female 1950-2000 2000-2015 63
Bayes(mod) 0.011 0.81 0.89 0.95
Bayes 0.011 0.81 0.90 0.95
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